Agilent Technologies (NYSE:A) Price Target Lowered to $150.00 at Bank of America

Agilent Technologies (NYSE:A) had its target price decreased by equities researchers at Bank of America from $153.00 to $150.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Bank of America‘s price objective points to a potential upside of 8.58% from the stock’s previous close.

Several other research firms have also weighed in on A. UBS Group boosted their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. Wells Fargo & Company decreased their price objective on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a report on Monday. TD Cowen raised their target price on Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. StockNews.com lowered Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, November 26th. Finally, JPMorgan Chase & Co. cut their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Agilent Technologies has a consensus rating of “Hold” and an average target price of $143.36.

Agilent Technologies Price Performance

Shares of Agilent Technologies stock traded down $2.76 during mid-day trading on Friday, reaching $138.15. 309,085 shares of the stock traded hands, compared to its average volume of 1,716,960. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57. The business has a 50-day moving average of $136.87 and a 200 day moving average of $136.60. The stock has a market capitalization of $39.69 billion, a PE ratio of 31.15, a PEG ratio of 4.48 and a beta of 1.07. Agilent Technologies has a fifty-two week low of $124.16 and a fifty-two week high of $155.35.

Agilent Technologies (NYSE:A) last issued its earnings results on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The business had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The company’s quarterly revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.38 earnings per share. On average, analysts predict that Agilent Technologies will post 5.56 EPS for the current year.

Insider Buying and Selling at Agilent Technologies

In related news, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the sale, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. This trade represents a 19.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Institutional Investors Weigh In On Agilent Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. lifted its stake in shares of Agilent Technologies by 2.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 9,910 shares of the medical research company’s stock valued at $1,285,000 after purchasing an additional 226 shares in the last quarter. Blue Trust Inc. increased its holdings in Agilent Technologies by 331.6% in the 2nd quarter. Blue Trust Inc. now owns 4,148 shares of the medical research company’s stock valued at $538,000 after purchasing an additional 3,187 shares in the last quarter. Brookstone Capital Management raised its holdings in shares of Agilent Technologies by 14.9% during the 2nd quarter. Brookstone Capital Management now owns 1,698 shares of the medical research company’s stock valued at $227,000 after buying an additional 220 shares during the period. Gradient Investments LLC grew its position in Agilent Technologies by 196.1% in the second quarter. Gradient Investments LLC now owns 832 shares of the medical research company’s stock valued at $108,000 after acquiring an additional 551 shares in the last quarter. Finally, Marshall Financial Group LLC acquired a new stake in Agilent Technologies during the 2nd quarter valued at $1,058,000.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.